Par Drugs And Chemicals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 08, 2025.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved audited standalone financial results for Q4 FY25 and full year ended March 31, 2025, with an unmodified auditor opinion. For FY25, revenue from operations rose modestly to Rs. 10,097.35 lakh (vs Rs. 9,564.04 lakh in FY24), but net profit fell to Rs. 1,335.79 lakh (vs Rs. 1,450.10 lakh), and EPS dipped to Rs. 10.86 (vs Rs. 11.78). Q4 FY25 revenue was Rs. 2,232.99 lakh with a net profit of Rs. 165.10 lakh. The balance sheet remained debt-free with total equity of Rs. 9,897.49 lakh and cash of Rs. 2,757.72 lakh, while investments jumped sharply to Rs. 2,507 lakh from Rs. 1.19 lakh. The auditor flagged a Key Audit Matter: the company executed a slump sale of its primary API unit (which contributed over 99% of revenue) and plans to pivot into clean energy, real estate, and capital markets. No investor complaints were pending.
Shareholders should note the company has sold its core revenue-generating API business and is repositioning into entirely new sectors, raising execution and going-concern risk despite a clean audit. Short-term financials show declining profits even on the existing business, so the stock will likely be viewed as a restructuring/rerating story rather than an operating play in the near term.